Stock listing
A2JQN1 Stock Price, News, Filings & Events — Replimune Group, Inc.
Selected listing: A2JQN1 · LS · EUR · DE
This page tracks Replimune Group, Inc.'s A2JQN1:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2JQN1:LS. A2JQN1:LS is the stock-level entry point for investors researching Replimune Group, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2JQN1:LS
- Asset type
- Stock
- Market cap
- $1.22B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Replimune Group, Inc. A2JQN1:LS stock context
This page tracks Replimune Group, Inc.'s A2JQN1:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2JQN1:LS. A2JQN1:LS is the stock-level entry point for investors researching Replimune Group, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Replimune Group, Inc.
Replimune to Present at the Cantor Global Healthcare Conference 2026
September 3, 2026
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
August 14, 2026
Replimune Announces Pricing of $150 Million Underwritten Offering
August 10, 2026
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
July 30, 2026
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
June 29, 2026
Replimune Group, Inc. earnings calls
Research Replimune Group, Inc.
Replimune Group, Inc. investor report
Review AI stock analysis and investor report context for A2JQN1:LS.
Replimune Group, Inc. company profile
View the public company page for Replimune Group, Inc. on 6ix.
Replimune Group, Inc. news
Read company news and market updates connected to Replimune Group, Inc..
Replimune Group, Inc. investor events
Find investor webinars, events, and replay context for Replimune Group, Inc..
Alternate listings
REPL:NASDAQ
US · USD
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:GETTEX
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
A2JQN1:LSX
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
REPL:BOATS
US · USD
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:SWB
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:TRADEGATE
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:FWB
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:HAM
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:MUN
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.
7R8:DUS
DE · EUR
Alternate listing for Replimune Group, Inc.; the primary context on this page is A2JQN1:LS.